Publications by authors named "Timothy Yap"

Claim this Profile
F
FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers.
Olanrewaju O Okusanya, Gabriela I Patilea-Vrana, Anthony Sireci, Alexia Iasonos, Brad A Davidson, Timothy A Yap

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.
Timothy A Yap, David J Kwiatkowski, Ibiayi Dagogo-Jack, Michael Offin, Marjorie G Zauderer

Nat Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen.
Nealia C House, Maxine M Chen, Sima Khazaei, Victoria Brown, Philip Ramsden, Timothy A Yap

NPJ Breast Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor DNA as a biomarker in early phase clinical trials.
Harold N Tan, Mitchell J Elliott, Ian M Silverman, Lillian L Siu, Timothy A Yap

Cancer Cell· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors.
Lillian L Siu, Timothy A Yap, Sofia Genta, Gregory Pennock, Christine Hicking

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline Mutations as Cancer Drug Targets.
Tin-Yun Tang, Karen Colbert Maresso, Joanne Ngeow, Eduardo Vilar, Timothy A Yap

Cancer Discov· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline PARP-1 PET imaging in patients with advanced solid tumors with DNA damage response mutations.
Tarek Daoud, Jiansong Chen, Peng Wei, Franklin Wong, Timothy A Yap

Eur J Nucl Med Mol Imaging· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognosis and treatment response stratification according to loss of proofreading (LOP) variants.
Giulia Maddalena, Fadl A Zeineddine, Saikat Chowdhury, Mohammad A Zeineddine, Abdelrahman M Yousef, Timothy A Yap

J Immunother Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
YAP1 Depletion Enhances TAZ and its Complexation with TEAD4 and AP-1 Heterodimer C-JUN/FOSB to Promote Gastric Cancer Progression and Metastases.
Jingjing Wu, Dipti Athavale, Curt Balch, Junsong Zhao, Gengyi Zou, Timothy Anthony Yap

bioRxiv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects.
Timothy A Yap, David S P Tan, Anastasios Stathis, Geoffrey I Shapiro, Satoru Iwasa

Cancer Discov· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response-Deficient Tumors.
Ian M Silverman, Joseph D Schonhoft, Benjamin Herzberg, Arielle Yablonovitch, Errin Lagow, Timothy A Yap

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drugging the DNA damage response in the clinic: going beyond PARP.
Carlos Torrado, Alvaro Gonzalez-Ortiz, Camila B Xavier, Harold N Tan, Natalie Y L Ngoi, Timothy A Yap

Expert Rev Anticancer Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Yap et al. Real-Time Imaging of Retinal Ganglion Cell Apoptosis. 2018, 60.
Timothy E Yap, Piero Donna, Melanie T Almonte, Maria Francesca Cordeiro

Cells· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations.
Kaushik Varadarajan, Christian X Cruz Pico, Kurt W Evans, Maria Gabriela Raso, Yasmeen Qamar Rizvi, Timothy A Yap

Mol Cancer Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies.
Federica Giugliano, Carmine De Angelis, Barbara Pistilli, Giulia Viale, Giampaolo Bianchini, Timothy A Yap

Cancer Treat Rev· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit.
Camila Braganca Xavier, Clark R Andersen, JoAnn Lim, Julian H Slade, Stacie A Bean, Timothy A Yap

Cancer Res Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study.
Timothy A Yap, Patricia LoRusso, Rowan E Miller, Rebecca Kristeleit, Amanda G Paulovich

Br J Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib.
Jatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann, Timothy A Yap, Ruth Plummer, Jayaprakasam Bolleddula

Clin Pharmacol Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
USP1 inhibition: A journey from target discovery to clinical translation.
Carlos Torrado, Nicholas W Ashton, Alan D D'Andrea, Timothy A Yap

Pharmacol Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors.
Timothy A Yap, Olivier Rixe, Capucine Baldini, Ursa Brown-Glaberman, Sergey Efuni

Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity.
Timothy A Yap, Mike I Walton, Kyla M Grimshaw, Robert H Te Poele, Paul D Eve

Clin Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanoma.
Natalie Y L Ngoi, Ian M Silverman, Adrienne Johnson, Chenfeng Meng, Joseph D Schonhoft, Timothy A Yap

NPJ Precis Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unlocking the therapeutic potential of ATR inhibitors: Advances, challenges, and opportunities in cancer therapy.
Tejaswini P Reddy, Timothy A Yap

Clin Transl Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies.
Jay Jacoby, Deva Mahalingam, Angela Alistar, Edward Garmey, Syed Kazmi, Timothy A Yap

J Immunother Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poly(adenosine diphosphate ribose) polymerase inhibition in isocitrate dehydrogenase 1 and 2-mutant tumors: Bridging science with the clinic.
Elise Nassif Haddad, Milind M Javle, Timothy A Yap

Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis